Vision sciences Inch. (NASDAQ: ) recently saw its Executive Vice President of Research and Development, Manohar K. Raheja, make a significant purchase of the company’s common stock. Raheja acquired 3,376 shares at $3.89 per share on Dec. 3, 2024, according to a filing with the Securities and Exchange Commission. This transaction has a total value of $13,132. After this purchase, Raheja’s total ownership in the company is 106,000 shares. InvestingPro data shows that the company maintains a strong balance sheet with more cash than debt, although stock price movements remain quite volatile. For deeper insight into insider trading patterns and 8 additional ProTips, consider exploring the comprehensive Pro Research Report available at InvestingPro.
In other recent news, Sight Sciences, Inc. reported a smaller year-over-year increase in revenue in its third-quarter earnings call despite results that fell short of expectations. The company’s third-quarter revenue rose 1% year-over-year to $20.2 million, with surgical glaucoma revenue at $18.6 million. However, it witnessed an 8% sequential decline in surgical glaucoma revenue and a decline in OMNI device usage due to competition and uncertainty of the LCD process.
Despite these setbacks, Sight Sciences remains optimistic about growth in the surgical glaucoma and dry eye segments in 2025. The company is challenging the 2025 Medicare final payment rule, which did not grant device-intensive status to OMNI’s procedures, and is focused on improving its sales performance and strategic positioning.
Recent developments include the appointment of Dr. MK Rahej as Executive Vice President of Research and Development to advance their surgical glaucoma development plan. Furthermore, Sight Sciences has performed over 200,000 OMNI and 60,000 TearCare procedures, demonstrating the company’s continued commitment to improving patient care and expanding market access.
This article was generated with the help of AI and reviewed by an editor. See our T&C for more information.
